The collaboration was announced on July 5, 2017. Under the terms of the agreements, BeiGene has acquired Celgene's commercial operations in China and assumed commercial responsibility for Celgene's approved therapies in China (Abraxane, Revlimid, and Vidaza) and pipeline agent CC-122. Celgene has received exclusive rights to develop and commercialize BeiGene's investigational anti-PD1 antibody, BGB-A317, for solid tumors in the United States, Europe, Japan, and the rest of the world outside of Asia. BeiGene will receive an aggregate of $413 million from Celgene in upfront licensing fees and equity investment, and will be eligible for up to an additional $980 million in development, regulatory, and sales milestones, as well as royalties on future sales of BGB-A317.
No comments:
Post a Comment